Sunday 22 November 2026 Live: Iran war Stories Browse Wire Subscribe
Faultline Journal — home

EconomicsAnalysis

Bayer's $7.25bn Roundup Settlement Clears Court, Closing a Long Chapter

A Missouri judge has approved the payout to roughly 65,000 claimants, but some federal cases and the science dispute remain unresolved.

Bayer's $7.25bn Roundup Settlement Clears Court, Closing a Long Chapter

Reporting drawn from The Guardian World. Analysis and editorial framing by the Faultline Journal Editorial Desk.

The settlement reduces Bayer's exposure, but it does not settle the underlying argument over glyphosate.

A Missouri state judge has approved Bayer's $7.25bn settlement of lawsuits alleging that its Roundup weedkiller causes cancer, according to The Guardian. Judge Timothy Boyer, sitting in St Louis, found the agreement "fair, reasonable and adequate" and overruled objections that individual payouts would be too low compared with sums paid to claimants who settled earlier.

The approval matters because it addresses litigation that has hung over the German company for close to a decade. Bayer faced approximately 65,000 claims in US state and federal courts from people who said they developed cancer after using Roundup at home or at work. The settlement, announced in February, was intended to resolve nearly all current and future Roundup claims in the United States. Boyer also noted that delaying payouts could force victims, including those whose cancer is terminal, to wait "an indeterminate number of years" for payment.

Bayer's chief executive, Bill Anderson, called the court's final approval "a decisive milestone in the company's strategy to mitigate the risks of both pending and future Roundup litigation". The financial context is stark. Bayer bought Monsanto, which produces the weedkiller, for $63bn in 2018, and its share price has fallen 46% since then, the report says. The company settled much of the Roundup litigation for $10.9bn in 2020 but failed to win court approval of a $1.25bn settlement covering future claims.

The timing reflects a legal shift as much as a commercial calculation. The approval came five months after the US supreme court overturned a $1.25m jury award to John Durnell, a Missouri man who blamed years of glyphosate exposure for his non-Hodgkin lymphoma. In a 7-2 decision, the court agreed with Bayer that a federal law regulating pesticides barred failure-to-warn claims brought under state law, undercutting a central pillar of many lawsuits. Christopher Seeger, a lawyer for many plaintiffs, said the Durnell decision narrowed victims' ability to pursue claims in court, adding that he looked forward to getting relief to them "as quickly as possible".

Bayer has long maintained that Roundup and its active ingredient glyphosate are safe, and that decades of studies have shown glyphosate does not cause cancer. That position has not been tested by this settlement, which buys peace rather than scientific vindication. The agreement also excludes some lawsuits still pending in federal court; Bayer has said about 200 such cases were still being litigated and that the supreme court decision gave it strong defences. Lawyers for objecting victims did not immediately respond to requests for comment, according to the report.

What remains unknown is how quickly the roughly 65,000 claimants will actually be paid, how the sums will be distributed among them, and whether the excluded federal cases will produce further liabilities or fresh legal challenges. The settlement reduces Bayer's exposure, but it does not settle the underlying argument over glyphosate, which continues in regulators, researchers and courtrooms beyond this judgment.

BayerRounduplitigationglyphosateMonsanto